| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 18, 2025 |
| Accession Number: | 0001213900-25-077471 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/7/2022 | $7.00 | Buy | Maxim Group |
F-3 - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
Maxim Group initiated coverage of NeuroSense Therapeutics with a rating of Buy and set a new price target of $7.00
Business, regulatory and clinical updates will be provided CAMBRIDGE, Mass., Nov. 3, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that it will host an investor update meeting on December 8, 2025 at 8:30 a.m. Eastern Time. The Company plans to provide status updates about its near-term milestones and objectives: Phase 3 PARAGON study initiation (ALS)Notice of Compliance with conditions (NOC/c) submission in CanadaStatus of the binding term sheet executed in December 2024RoAD Phase 2 program (Alzheimer's disease)Investors interested
CAMBRIDGE, Mass., Oct. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced new positive findings based on plasma samples from its Phase-2b PARADIGM study. These results indicate that PrimeC produced robust, statistically significant reductions in multiple microRNAs that are consistently implicated in Alzheimer's disease pathology - changes that reflect reduction of neuroinflammatory and neurodegenerative activity. Key Highlights - PrimeC treatment significantly reduced several AD-associated microRNAs, including miR-146a-5p (p=0.007
Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profile CAMBRIDGE, Mass., Sept. 10, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced positive initial results from its collaboration with NeuroKaire in the ongoing RoAD Phase 2 clinical trial evaluating PrimeC for Alzheimer's disease (AD). Using NeuroKaire's proprietary technology to generate brain cells from each patient's blood, analysis of samples from clinically characterized AD patients demonstrated that: Pri
SC 13G - NeuroSense Therapeutics Ltd. (0001875091) (Subject)
SC 13G/A - NeuroSense Therapeutics Ltd. (0001875091) (Subject)
SC 13G/A - NeuroSense Therapeutics Ltd. (0001875091) (Subject)
Novel Vaccine Company Expands Leadership Team and Establishes US Presence SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer (CEO). He also joins the Board of Directors. Sumi Biswas, the company's co-founder, remains President and a Director and becomes Chief Scientific Officer (CSO). With the addition of Leuchtenberger, SpyBiotech establishes its presence in the United States with an office in Cambridge, Massachusetts. Mark Leuchtenberger recently served as Executive Chairman for Aleta Biotherapeutics and previously as CEO o
Top-Line Results from 6-month double-blind Phase 2b PARADIGM trial with NeuroSense's lead drug candidate for ALS, PrimeC, include: PrimeC achieved primary safety and tolerability endpoints with a safety and tolerability profile comparable to placeboMeaningful slowing of disease progression: 29% difference (P=0.12) in favor of ALSFRS-R outcome for patients treated with PrimeC vs placeboSlow Vital Capacity: observed a positive trend in favor of patients treated with PrimeC compared to placeboNeurofilament biomarker results from Biogen collaboration expected in January 2024Primary biomarker endpoints and exploratory biomarkers from this trial, expected in H1 2024Company to host webcast conferen
Data to be announced in a premarket press release followed by a conference call at 8:30 am ET CAMBRIDGE, Mass., Dec. 4, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a company developing treatments for neurodegenerative diseases, today announced it will report new data from the randomized, placebo-controlled, double-blind segment of its ongoing Phase 2b amyotrophic lateral sclerosis (ALS) trial (PARADIGM) of its lead drug candidate PrimeC. The data will include primary safety and tolerability endpoints as well as secondary clinical efficacy outcome measures: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) and Slow Vital Capacity (S
CAMBRIDGE, Mass., Dec. 1, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its financial results for the quarter ended September 30, 2022 and provided a business update. "During and immediately following the end of the third quarter, NeuroSense achieved multiple milestones, including FDA acceptance of our IND and approval from the Italian Medicines Agency allowing us to commence patient enrollment in the U.S. and Europe for our Phase 2b ALS study, which we expect to begin in the coming weeks. With over $8.4 million in cash and short-term deposits on our balance sheet at the e